Background: Th e aim of this study is to report the short-term results of catheter-directed foam sclerotherapy (CDFS) in the treatment of axial saphenous vein incompetence. Patients and methods: Data of all patients undergoing CDFS for symptomatic primary incompetence of the great or small saphenous vein were prospectively collected. Treatment results in terms of occlusion rate and patients' grade of satisfaction were analysed. All successfully treated patients underwent clinical and duplex follow-up examinations one year postoperatively. Results: Between September 2006 and September 2010, 357 limbs (337 patients) were treated with CDFS at our institution. Based on the CEAP classifi cation, 64 were allocated to clinical class C3 , 128 to class C4, 102 to class C5 and 63 to class C6. Of the 188 patients who completed the one year follow up examination, 67 % had a complete and 14 % a near complete obliteration of the treated vessel. An ulcer-healing rate of 54 % was detected. 92 % of the patients were satisfi ed with the results of treatment. We registered six cases of thrombophlebitis and two cases of venous thromboembolism, all requiring treatment. Conclusions: Th e short-term results of CDFS in patients with axial vein incompetence are acceptable in terms of occlusion and complications rates.
Introduction
Th e use of ultrasound guided foam sclerotherapy to treat varicose veins has rapidly increased during the last decade. Foam sclerotherapy is cheap, does not require anaesthesia, is effective and has an acceptable safety profi le [8, 18] . Th e treatment rationale is that sclerosant agents damage the endothelium irreversibly by disrupting cell membranes resulting in sustained vasospasm and vessel obliteration [15] .
Th e direct instillation of sclerosant agents as "microfoam" with carbon dioxide or air made it become an attractive treatment for axial refl ux in the great or small saphenous vein (GSV and SSV) [2, 5, 14, 15] . A large number of reports have documented the potential advantages of this technique for treating incompetent axial veins [2, 3, 5, 11, 14, 15, 21, 24] . Publications have focused on foam preparation techniques and the necessary amount of sclerosant agent.
Th e absence of a standard delivery technique makes foam sclerotherapy diffi cult to compare with other endovascular ablation techniques such as endovenous laser therapy (ELT) and radiofrequency ablation (RFA) [14] . In a previous report, we presented a technique intended to optimise and standardise foam sclerotherapy of the GSV and SSV in patients with axial refl ux [12] . In this extended analysis further follow-up data including safety and effi cacy of the method, are reported.
Patients and methods
All patients undergoing CDFS due to incompetence of the GSV and/or the SSV in a 4-year period were prospectively registered in an appropiate ad hoc database. All patients gave informed consent and approval was obtained from our local Ethics committee. Th e study and the examination protocols have been previously described [12] . Clinical data were collected in a standardized manner at the fi rst visit as well as at every follow up control. Accordingly, all patients were investigated using duplex ultrasound (US) imaging to assess the extent of superfi cial and deep venous incompetence in an accredited vascular laboratory. CDFS was taken in consideration as a treatment option in patients with advanced disease, i.e. venous insuffi ciency associated with eczema, recurring thrombophlebitis, skin discoloration, active or previously healed leg ulcer. Th e aim of the treatment was primarily to eliminate axial venous refl ux rather than to eliminate varicosities. A short term control consisting of a clinical as well as an US examination 4 week postoperatively was conducted in the fi rst 81 patients of the study cohort. Information regarding the remaining patients was collected by telephone interviews and a review of clinical records from the emergency departments of the region and from general practitioners. All successfully treated patients were invited to a one-year clinical and duplex follow-up examination. In particular, we focused our attention on the skin status, registering the presence of excema, new ulcerations or the healing of previous ulcers. Furthermore, the degree of satisfaction (0 not satisfi ed, 1 satisfi ed, 2 very satisfi ed) based on overall improvement of symptoms was recorded. We defi ned the treatment as successful when the axial vein appeared to be completely occluded at the US examination. Partial success was defi ned as the obliteration of at least 70 % of the vessels lumen. In case of symptomatic recurrence a further CFDS was undertaken.
Technical aspects
Duplex ultrasonography was conducted using a high resolution transducer (10 MHz, Logiq 9, General Electric, Milwaukee, USA) on an adjustable examination couch, which could be tilted to 45 degrees in order to unmask incompetence of the deep as well as the superfi cial venous system. Th e cut-off value for refl ux in the superfi cial and deep calf veins was set at 500 msec as suggested by Labropoulos et al. [13] . During treatment the patient in the tilted position supported their weight with the contralateral leg to facilitate puncture of the vein. Patients lay supine during treatment of the GSV with the preferred puncture site normally 3 -5 cm below the knee. When lying prone for treatment of the SSV, this was punctured 1 -2 cm below the sapheno-popliteal junction. A small amount of local anaesthetic (1 -2 ml mepivacain, Carbocain 1 % ®, Astra Zeneca, Södertälje, Sweden) was infi ltrated at the puncture-site to avoid local spasm. Th e vein was punctured under ultrasound guidance with an 18G standard vascular access needle. A guide wire (Angiodyn SFC 150 -035, B.Braun, Melsungen, Germany) was inserted into the dilated vessel by the Seldinger technique and advanced under US guidance to the sapheno-femoral/popliteal junction. Aft er a small cutaneous stab incision a 5Fr. introducer sheath (RCFW-5.0 -38-45 William Cook Europe, Bjaeverskov, Denmark) was advanced over the guide wire. Th e patient was tipped back to a horizontal position and the leg was elevated 30 degrees using a wedge-pillow. Th e introducer tip was placed up to 1 to 2 cm distal to the sapheno-femoral/popliteal junction. Sclerosant foam was prepared in a liquid/air ratio of 1:/4 using 2 ml of 3 % polidocanol (Aethoxysklerol®, Kreussler, Wiesbaden, Germany) in order to produce 10 ml of foam. In our experience this ratio combined with cooling of the sclerosant in ice rendered an acceptable viscosity. Th e GSV or the sapheno-popliteal junction were manually compressed proximal to the introducer tip for treatment of the GSV or the SSV respectively. Th e introducer was loaded with foam (usually 2 ml). When the foam reached the introducer-tip the sheath was slowly withdrawn, while injecting 8 -10 ml of sclerosing foam in the GSV and 4 -8 ml in the SSV. Th e introducer was then removed and the GSV or SSV compressed in order to prevent the foam from passing uncontrollably into the deep venous system. Treatment results were verifi ed with US. Th e patient was then mobilized immediately and required to walk for fi ve minutes and advised to wear long compression stockings during the fi rst postoperative week. Knee length compression stockings were adopted from week two to week eight.
Results
Between September 2006 and September 2010 337 patients (357 limbs) were treated with CDFS at our vascular centre. Demographic data and severity of venous disease are shown in Table I . Of the 357 limbs, 21 were treated owing to recurrence aft er previous surgical treatment for non axial varicose veins (n = 10) or previous CDFS (n = 11). 22 patients had clinical signs and symptoms of previous deep vein thrombosis, and, additionally, 12 cases had primary deep vein incompetence based on ultrasound examination. Eleven patients were on oral anticoagulants at the time of treatment.
Primary
No patient developed chest discomfort, dry cough, dizziness, migraine, nausea or visual disturbances at the time of treatment. The GSV was treated with a median of 8,7 ml foam while the treatment of the SSV required a median of 7,6 ml sclerosant. Six patients required low molecular weight heparin due to painful treatment-related thrombophlebitis a week aft er the procedure. In Table II the results of treatment 1 year postoperatively are summarized. 92 % of the treated patients were either satisfi ed or very satisfi ed with the result of treatment. Eleven patients were treated for their venous disease whilst on long term oral anticoagulation with cumarin, seven for atrial fi brillation and four due to previous deep vein thrombosis. Eight of the 11 patients had occluded saphenous trunks one week aft er treatment despite ongoing ordinary anticoagulation. Clinical improvement was sustained in these patients at 1 year follow up. Of the 63 patients treated in class C6, 47 underwent the 1-year follow-up examination. 35 of those were found to have healed ulcers. In the remaining cases, four had combined venous and arterial disease. Th ree patients developed a new ulcer in association with venous refl ux due to recanalisation of the GSV at 1 year. One patient with a chronic ulcer in spite of treatment was later found to have a squamous cell carcinoma of the skin. We registered two cases of treatment -related thromboembolism. A 62 year old female patient with a previous history of DVT and ongoing oestrogen replacement therapy was treated successfully but suffered pulmonary embolism verifi ed by CT-angiograhpy nine days later. No DVT was detected by duplex US. Th e patient was treated with intravenous unfractioned heparin followed by cumarin and made an uneventful recovery. A 59-year-old male patient with painful thrombophlebitis was managed initially with non-steroidal anti-infl ammatory drugs and low molecular weight heparin (enoxaparin). In this case as well, US could not detect any sign of DVT. However, a CT-scan revealed ilio-femoral thrombosis and the patient underwent locoregional thrombolysis, which unmasked a tight stenosis of the left common iliac vein requiring endovascular treatment as well as oral anticoagulation. Th e patient recovered well and is presently free of venous incompetence-related symptoms.
Discussion
Th is clinical series shows that CDFS has acceptable results in the treatment of incompetent GSV and SSV. Th e complication rate was low (see Table III Regarding the foam itself, Cavezzi [6] had already reported that the characteristics of home-made foam greatly infl uence the choice of the gas component, the liquid-to-gas ratio and the type of syringes. Larger needles are preferred for injection of foam while long catheters seem to be a valid alternative especially when combined with tumescence to minimise the saphenous diameter.
Th e distribution of foam achieved by direct puncture technique is unpredictable [10, 16] . Direct puncture sclerotherapy may allow larger amounts of the foam to pass into the deep veins [18] . Th is "spill-over" of foam occurs mainly via perforators of the thigh to the deep venous system and can potentially be reduced using catheter-directed delivery into defi ned vessel-segments and a low injection pressure under withdrawal of the catheter [7] . However, this aspect needs further investigation. Th e total rate of ulcer healings was 54 % at 1 year, and is low if compared with other experiences [17, 18, 20] . Th is can be explained by our decision not to mention those patients that still have ulcers healing later aft er successful treatment. Foam-sclerotherapy is oft en referred to as ultrasound-guided and -controlled. Th is implies accuracy and safety. In most studies ultrasound is used to aid the puncture of the GSV and then to compress the saphenofemoral junction to prevent foam migration. However, the ultrasound transducer is also used to guide the foam using external massage pressure or "milking"-techniques [1, 2, 5, 9, 23]. In our experience using ultrasound for these purposes is technically diffi cult. Careful delivery of foam to the intended site of action using a sheath along the length of the axial vein is technically easier and more reliable. Th e immediate success rate and the degree of refl ux at one-year follow-up of catheter-directed foam sclerotherapy compares well with the results of ELT or RFA treatment [14, 24] . However, the fact that the procedure does not cause ecchymosis and does not require anaesthesia speaks in favour of catheter-directed foam sclerotherapy [7] . Furthermore, in patients with recurrent varicose veins foam sclerotherapy has also shown positive haemodynamic results refl ecting signifi cant improvement of the venous function [4, 26, 27] . Th is study has limitations since only half the original patients treated attended the one-year follow-up. We did not record haemodynamic data before and aft er the treatment to assess the effi cacy of our treatment on venous function. We are therefore unable to comment on whether CDFS can be used to improve venous function in order to prevent further worsening and complications. Th e short and incomplete length of follow up does not allow any sort of recommendation. However, we believe that the high degree of patients` acceptance as well as the positive early results should be taken into consideration.
In conclusion, the use of this catheter based technique facilitates foam sclerotherapy with a high primary-and acceptable short-term occlusion rates, and low numbers of complications. Further studies are required to evaluate how the migration of foam into the common femoral vein can be diminished and whether the techniques used in this study of leg elevation and manual compression provide any advantage.
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